Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06720766). This is a study registration, not published results. Lead sponsor: The Third People's Hospital of Chengdu. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 565 participants (ACTUAL). Conditions: Fatty Liver Disease. Interventions: DIAGNOSTIC_TEST: FibbroScan and biopsy. Primary outcome measures: Diagnostic accuracy , Through study completion, an average of 1 year; Cut-off values , Through study completion, an average of 1 year. Brief summary: The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity. The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.